• Search
  • Login
  • Register
Menu
  • BJMO
  • Home
  • News
  • CongressUpdate
  • Specials
  • Links
All
  • All
  • BJMO articles
  • Blog articles
  • Specials
Forgot Password? Not a member yet? Register here
News > CongressUpdate
ASCO GI 2023

Zolbetuximab plus chemotherapy prolongs survival in CLDN18.2+/HER2- gastric/GEJ adenocarcinoma

Read more
subscribe Latest issue All issues Newsletters
Index latest issue
  • The prognostic significance of disseminated tumour cells in bone marrow in patients with operable breast cancer: An updated analysis
  • Burnout in resident physicians
  • Simply the B(r)east: Endothelial cell heterogeneity in health and disease
  • Highlights of the ASCO Gastrointestinal Cancers Symposium 2023
  • Journal Scan
  • New oncology reimbursements in Belgium
  • Introducing the new BSMO President (2023–2026): Interview with Prof. E. de Azambuja
ASCO 2022

COVID-19 pandemic impacted on screening and care of patients with rare hereditary cancers

Read more
EAU 2022

Surgical treatment update for RCC patients from European urology congress

Read more
ASCO 2022

Highlights of ASCO 2022

Read more
EADO 2022

Highlights EADO 2022

Read more
ELCC 2022

Sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metast...

Read more
ELCC 2022

Osimertinib as neoadjuvant treatment for resectable stage II-IIIB EGFR-mutated lung adenocarci...

Read more
ELCC 2022

Savolitinib in the treatment of patients with non-small cell lung cancer and MET exon 14 skipp...

Read more
ASCO GI 2022

Combination of docetaxel, cisplatin and 5-FU as a new standard neoadjuvant treatment for oesop...

Read more
1 2 3 4 5 6 Next
Top

Join our newsletter

  • This field is for validation purposes and should be left unchanged.
  • About BJMO
  • Ads & sponsoring
  • Vacancies
  • Disclaimer
  • Privacy
  • Contact

BJMO is published by Ariez International BV, Westzijde 22, 1506 EE Zaandam, The Netherlands

© BJMO 2023